Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Horning, S. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Horning, S. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:S23-S27, 2000
© 2000 European Society for Medical Oncology

Symposium Articles

Follicular lymphoma: Have we made any progress?

S. J. Horning

Department of Medicine (Oncology and Bone Marrow Transplantation), Stanford University Medical Center Stanford, CA, USA

Correspondence to: S. J. Horning, MD Department of Medicine (Oncology and Bone Marrow Transplantation) Stanford University Medical Center 1000 Welch Road, Suite 202 Palo Alto, CA 94304 USA

Follicular lymphomas are characterized by relatively long median survivals and a continuous pattern of relapse. The heterogeneity in these diseases is increasingly appreciated, leading to concerted efforts to define prognostic factors and risk-adapted strategies. The status of multiple options for treatment including interferon, fludarabine, dose intensification with autologous transplantation, therapy targeting the CD20 antigen and novel approaches is reviewed. The long natural history of follicular lymphoma requires mature data for accurate analysis. However, the achievement of molecular remission as a surrogate endpoint is under active investigation.

This is an exciting era for the clinical investigation of follicular lymphoma given the large number of candidate therapies and their potential combinations and permutations. Although the goal of primary treatment remains durable remission and cure, the sequential application of effective, non-cross-resistant treatments may also result in a prolongation of median survival time. It is essential that physicians treating patients with follicular lymphoma demonstrate restraint in the application of new treatments and cooperate in the study of new therapies in carefully designed phase II and phase III trials.

fludarabine, follicular lymphoma, interferon, Rituximab, stem-cell transplantation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Ghielmini, K. Rufibach, G. Salles, L. Leoncini-Franscini, C. Leger-Falandry, S. Cogliatti, M. Fey, G. Martinelli, R. Stahel, A. Lohri, et al.
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ann. Onc., October 1, 2005; 16(10): 1675 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. T. Swenson, J. E. Wooldridge, C. F. Lynch, V. L. Forman-Hoffman, E. Chrischilles, and B. K. Link
Improved Survival of Follicular Lymphoma Patients in the United States
J. Clin. Oncol., August 1, 2005; 23(22): 5019 - 5026.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Maartense, S. le Cessie, H. C. Kluin-Nelemans, P. M. Kluin, S. Snijder, P. W. Wijermans, and E. M. Noordijk
Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry
Ann. Onc., August 1, 2002; 13(8): 1275 - 1284.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.